MARKET

ATOS

ATOS

Atossa Therapeutics Inc
NASDAQ
0.8200
+0.0077
+0.95%
After Hours: 0.8000 -0.02 -2.44% 18:33 01/27 EST
OPEN
0.8200
PREV CLOSE
0.8123
HIGH
0.8399
LOW
0.7936
VOLUME
354.91K
TURNOVER
0
52 WEEK HIGH
1.620
52 WEEK LOW
0.5000
MARKET CAP
103.83M
P/E (TTM)
-4.2731
1D
5D
1M
3M
1Y
5Y
BRIEF-Atossa Therapeutics Issues Letter To Shareholders
Reuters · 4d ago
Atossa Therapeutics to Enroll 175 Patients for Mid-Stage Breast Cancer Trial
Atossa Therapeutics to Enroll 175 Patients for Mid-Stage Breast Cancer Trial
MT Newswires · 4d ago
BRIEF-Atossa Therapeutics Announces The Appointment Of Eric Van Zanten As Vice President, Investor And Public Relations
Reuters · 12/07/2022 13:42
BRIEF-Atossa Therapeutics Reports Q3 Loss Per Share Of $0.06
Reuters · 11/07/2022 21:54
Atossa Therapeutics GAAP EPS of -$0.06 in-line
Seekingalpha · 11/07/2022 21:52
Atossa Genetics Q3 EPS $(0.06) Down From $(0.04) YoY
Benzinga · 11/07/2022 21:29
Atossa Therapeutics Q3 Net Loss Widens from Year-Ago Period
Atossa Therapeutics Q3 Net Loss Widens from Year-Ago Period
MT Newswires · 11/07/2022 16:15
Atossa acquiring ~20% stake in Dynamic Cell Therapies to boost CAR-T development
Seekingalpha · 11/01/2022 15:22
More
About ATOS
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing medicines for breast cancer, other breast conditions and Covid-19. Its Covid-19 drugs under development, including the AT-H201 program, is for severely ill patients on ventilators, and AT-301 COVID-19 is a nasal spray. Its nasal spray formulation AT-301 is being designed to contain ingredients that can potentially block SARS-CoV-2 viral entry gene proteins in nasal epithelial cells by interfering with spike protein activation by host proteases, by masking receptor binding domains via electrostatic mechanisms, and by providing a generalized mucoadhesive epithelial barrier. AT-H201 program is to develop a therapy to improve lung and function like a chemical vaccine. It is also developing an oral formulation of Endoxifen to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy.

Webull offers kinds of Atossa Therapeutics Inc stock information, including NASDAQ:ATOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATOS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATOS stock methods without spending real money on the virtual paper trading platform.